Occam Places Jeb Ledell as COO at Aveo Oncology
AVEO Oncology (Nasdaq: AVEO) is a commercial stage, oncology-focused biopharmaceutical company. Aveo was acquired by LG Chem for $600M in October of 2022.
In late 2021, Occam placed Jeb Ledell as COO of AVEO. Jeb joined AVEO from Enzyvant Therapeutics, a biotech company dedicated to developing novel, transformative regenerative therapies with rare diseases, where he served as COO. Prior to Enzyvant, Jeb served as COO at Compass Therapeutics and Horizon Discovery Group.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.